Press Releases PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

Apr. 19	First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	CI
Feb. 07	Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PHASEBIO PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	22-10-31	AQ
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code	22-10-24	BU
PHASEBIO PHARMACEUTICALS INC : Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits (form 8-K)	22-10-24	AQ
PHASEBIO PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)	22-10-07	AQ
PHASEBIO PHARMACEUTICALS INC : Other Events (form 8-K)	22-09-27	AQ
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights	22-08-15	AQ
PhaseBio Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Recent Business Highlights - Form 8-K	22-08-12	PU
PHASEBIO PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-12	AQ
PHASEBIO PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-08-12	AQ
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights	22-08-12	BU
PHASEBIO PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	22-08-08	AQ
PHASEBIO PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	22-07-05	AQ
PHASEBIO PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)	22-05-20	AQ
PHASEBIO PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-05-16	AQ
PHASEBIO PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-16	AQ
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights	22-05-16	BU
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab	22-05-16	BU
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference	22-04-07	BU
PhaseBio Pharmaceuticals : Announces Positive Results from Phase 2b Trial for Bentracimab - Form 8-K	22-04-04	PU
PHASEBIO PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	22-04-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

Press Releases

Filters